# Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

> **NCT05743907** · PHASE4 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 231 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** DA-2811
- **DRUG:** Forxiga

## Key facts

- **NCT ID:** NCT05743907
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-25
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743907, "Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05743907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*